Roche’s Xeloda Gets Chinese Approval
This article was originally published in PharmAsia News
Executive SummaryChina's State FDA has given its approval to Roche Pharmaceuticals' Xeloda (capecitabine) oral drug for treating gastric cancer. The chemotherapy drug is considered more convenient than injectable versions because it has fewer side effects and avoids a chance of infections. China counts 400,000 people a year diagnosed with gastric cancer and a mortality rate of 300,000 a year, the third most fatal cancer in the country. (Click here for more
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.